Kathy D Miller MD

Oncology•Indianapolis, IN

Associate Professor of Medicine, Indiana University

Request Appointment

535 Barnhill Dr# ROUTE473Indianapolis, IN 46202
Book by Phone+1(317) 934-6798

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1997
Johns Hopkins UniversityResidency, Internal Medicine, 1991 - 1994
Johns Hopkins University School of MedicineClass of 1991

Certifications & Licensure

IN State Medical License 1994 - 2025
MN State Medical License 1997 - 1999
ND State Medical License 1997 - 1999
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Indianapolis Monthly Castle Connolly, 2011, 2013

Clinical Trials

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2002 Jan 29
Completed
Phase 3
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer Start of enrollment: 2005 Sep 01
Terminated
A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment Start of enrollment: 2007 Apr 01
Completed
Phase 1
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer Start of enrollment: 2007 Oct 01
Terminated
Phase 2
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer Start of enrollment: 2008 Apr 01
Completed
Not Applicable
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer Start of enrollment: 2008 Jul 01
Completed
Phase 1
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer Start of enrollment: 2008 Nov 01
Completed
Not Applicable
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
COMPLETED
PHASE2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
Completed
Phase 2
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 1
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC Start of enrollment: 2012 Jul 01
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
ACTIVE_NOT_RECRUITING
PHASE3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
COMPLETED
PHASE2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
COMPLETED
PHASE3
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
COMPLETED
PHASE1
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer Start of enrollment: 2020 Apr 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.
Sneha Phadke, Kathy D Miller, Ami Shah, Oana C Danciu, Yi Chen
Breast Cancer Research and Treatment. 2025-08-01
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELE...
Amy S Clark, Fengmin Zhao, Paula Klein, Alberto J Montero, Carla Falkson
Clinical Cancer Research. 2025-07-01
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metast...
Erika P Hamilton, Manish R Patel, Virginia F Borges, Jane L Meisel, Meena Okera
Breast Cancer Research. 2025-07-01

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology

Lectures

Using the Neoadjuvant Approach in Developing Novel Therapies in ER+ Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Review and Interpretation of the 2012 San Antonio Breast Cancer Symposium
Indiana University School of Medicine, Indianapolis, Indiana - 1/19/2013
2012 ACCA Northeast Regional Conference
American Academy of Medical Administrators (AAMA), Wynnewood, Pennsylvania - 10/12/2012
2012 Best of ASCO San Diego
American Society of Clinical Oncology(ASCO), San Diego, California - 8/10/2012
2012 Best of ASCO Boston
American Society of Clinical Oncology(ASCO), Boston, Massachusetts - 8/3/2012
Join now to see all

Authored Content

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Press Mentions

Routine Checks for Cancer Metastases: A Help or Harm?June 25th, 2025
PATINA Trial Shifts Paradigm in HER2+/ER+ Breast Cancer Treatment, Prolonging Survival with Targeted Combination TherapyFebruary 28th, 2025
'Too Scared' to Deviate: When Is It Safe to De-Escalate TNBC Treatment?February 13th, 2025
Join now to see all

Grant Support

The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variabilityINDIANA UNIVERSITY INDIANAPOLIS2024–2029

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Tennessee Network 5
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
First Choice
First Health PPO
Great West PPO
HealthLink PPO
Highmark BCBS ClassicBlue
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Premera BCBS Heritage & Heritage Plus 1
Providence Health System Personal Option
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment

Kathy D Miller MD

Overview of Dr. Miller

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Authored Content

Press Mentions

Grant Support

Professional Memberships

Insurance Accepted

Viewing the full profile is available to verified healthcare professionals only.